These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35769574)

  • 1. Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia.
    García-Gómez E; Chapman E; García-Paba MB; Ocampo-Gómez J; Egea-Bermejo E; Garavito-De Egea G; Fang L; Sarrazola M; Sánchez-Caraballo JM; Serrano-Reyes C; Silva-Espinosa DL; Rojas-Mejía DV; Moreno SM
    Front Allergy; 2022; 3():902344. PubMed ID: 35769574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
    Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R
    J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H
    Chu CY; Al Hammadi A; Agmon-Levin N; Atakan N; Farag A; Arnaout RK; Kannenberg S; Kulthanan K; Mubarak A; Zaitoun F; Crowe S; Malfait S; Cooke K; Dekker EL
    World Allergy Organ J; 2020 Apr; 13(4):100117. PubMed ID: 32382379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
    Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
    Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America.
    Cherrez-Ojeda I; Maurer M; Bernstein JA; Vanegas E; Felix M; Ramon GD; Ensina LF; Larco Sousa JI; Matos Benavides EE; Cardona Villa R; Latour Staffeld P; Morfin-Maciel BM; Mori J; Wilches C P; Mata VL; Cherrez A
    World Allergy Organ J; 2019; 12(2):100011. PubMed ID: 30937137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines.
    Marín-Cabañas I; Berbegal-de Gracia L; de León-Marrero F; Hispán P; Silvestre JF
    Actas Dermosifiliogr; 2017 May; 108(4):346-353. PubMed ID: 28219634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results.
    Maurer M; Giménez-Arnau A; Ensina LF; Chu CY; Jaumont X; Tassinari P
    World Allergy Organ J; 2020 Sep; 13(9):100460. PubMed ID: 32983330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
    Metz M; Ohanyan T; Church MK; Maurer M
    J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both.
    Chen Y; Yu M; Huang X; Tu P; Shi P; Maurer M; Zhao Z
    World Allergy Organ J; 2021 Jan; 14(1):100501. PubMed ID: 33510832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review.
    Carrillo DC; Borges MS; García E; Egea E; Serrano CD
    World Allergy Organ J; 2014; 7(1):72. PubMed ID: 25566332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Urticaria: An Overview of Treatment and Recent Patents.
    Hon KL; Leung AKC; Ng WGG; Loo SK
    Recent Pat Inflamm Allergy Drug Discov; 2019; 13(1):27-37. PubMed ID: 30924425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expert consensus on the use of omalizumab in chronic urticaria in China.
    Zhao Z; Cai T; Chen H; Chen L; Chen Y; Gao X; Gao X; Geng S; Guo Y; Hao F; Hao G; Hu Y; Jin H; Jin Z; Li C; Li H; Li J; Li Y; Liang Y; Liu G; Liu Q; Long H; Ma L; Shang Y; Song Y; Song Z; Su X; Sui H; Sun Q; Sun Y; Tang J; Tong X; Wang H; Wang G; Wang L; Wang S; Xiang L; Xiao T; Xie Z; Ye L; Yu Y; Zhang C; Zhang L; Zhang S; Zheng R; Zhi L; Zhou W; Zou Y; Maurer M
    World Allergy Organ J; 2021 Nov; 14(11):100610. PubMed ID: 34934470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of the updosing of second-generation non-sedating H1 antihistamines in children with chronic spontaneous urticaria.
    Sarti L; Barni S; Giovannini M; Liccioli G; Novembre E; Mori F
    Pediatr Allergy Immunol; 2021 Jan; 32(1):153-160. PubMed ID: 32745323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
    Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature.
    Passanisi S; Arasi S; Caminiti L; Crisafulli G; Salzano G; Pajno GB
    Dermatol Ther; 2020 Jul; 33(4):e13489. PubMed ID: 32358910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Pediatric Chronic Spontaneous Urticaria: A Review of Current Evidence and Guidelines.
    Chang J; Cattelan L; Ben-Shoshan M; Le M; Netchiporouk E
    J Asthma Allergy; 2021; 14():187-199. PubMed ID: 33727832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
    Maurer M; Raap U; Staubach P; Richter-Huhn G; Bauer A; Oppel EM; Hillen U; Baeumer D; Reinhardt M; Chapman-Rothe N
    Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future therapies for treating chronic spontaneous urticaria.
    Maurer M; Vena GA; Cassano N; Zuberbier T
    Expert Opin Pharmacother; 2016 Jun; 17(8):1131-9. PubMed ID: 26918673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
    Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
    Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term management of chronic spontaneous urticaria with omalizumab.
    Pinto Gouveia M; Gameiro A; Pinho A; Gonçalo M
    Clin Exp Dermatol; 2017 Oct; 42(7):735-742. PubMed ID: 28649751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.